Maribavir (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Maribavir" in German language version.

refsWebsite

Global rank German rank

4^th place

7^th place

2^nd place

3^rd place

447^th place

751^st place

924^th place

87^th place

low place

68^th place

29^th place

doi.org

Karen K. Biron, Robert J. Harvey, Stanley C. Chamberlain, Steven S. Good, Albert A. Smith: Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. In: Antimicrobial Agents and Chemotherapy. Band 46, Nr. 8, August 2002, S. 2365–2372, doi:10.1128/AAC.46.8.2365-2372.2002, PMID 12121906.
Mark N. Prichard: Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. In: Reviews in Medical Virology. Band 19, Nr. 4, Juli 2009, S. 215–229, doi:10.1002/rmv.615, PMID 19434630, PMC 3777615 (freier Volltext).
Francisco M. Marty, Per Ljungman, Genovefa A. Papanicolaou, Drew J. Winston, Roy F. Chemaly: Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. In: The Lancet. Infectious Diseases. Band 11, Nr. 4, April 2011, S. 284–292, doi:10.1016/S1473-3099(11)70024-X, PMID 21414843.
David R. Snydman: Why did maribavir fail in stem-cell transplants? In: The Lancet. Infectious Diseases. Band 11, Nr. 4, April 2011, S. 255–257, doi:10.1016/S1473-3099(11)70033-0, PMID 21414844.

Eintrag EU/1/22/1672 im EU-Register für Humanarzneimittel, Europäische Kommission. Abgerufen am 24. November 2022.

Karen K. Biron, Robert J. Harvey, Stanley C. Chamberlain, Steven S. Good, Albert A. Smith: Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. In: Antimicrobial Agents and Chemotherapy. Band 46, Nr. 8, August 2002, S. 2365–2372, doi:10.1128/AAC.46.8.2365-2372.2002, PMID 12121906.
Mark N. Prichard: Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. In: Reviews in Medical Virology. Band 19, Nr. 4, Juli 2009, S. 215–229, doi:10.1002/rmv.615, PMID 19434630, PMC 3777615 (freier Volltext).
Francisco M. Marty, Per Ljungman, Genovefa A. Papanicolaou, Drew J. Winston, Roy F. Chemaly: Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. In: The Lancet. Infectious Diseases. Band 11, Nr. 4, April 2011, S. 284–292, doi:10.1016/S1473-3099(11)70024-X, PMID 21414843.
David R. Snydman: Why did maribavir fail in stem-cell transplants? In: The Lancet. Infectious Diseases. Band 11, Nr. 4, April 2011, S. 255–257, doi:10.1016/S1473-3099(11)70033-0, PMID 21414844.

Datenblatt Maribavir, ≥98% (HPLC) bei Sigma-Aldrich, abgerufen am 23. Dezember 2021 (PDF).